Discovery of Novel 2-Carbamoyl Morpholine Derivatives as Highly Potent and Orally Active Direct Renin Inhibitors-Reference-Cited by-同舟云学术

Discovery of Novel 2-Carbamoyl Morpholine Derivatives as Highly Potent and Orally Active Direct Renin Inhibitors

Published:2022-08-01 Issue:8 Volume:13 Page:1351-1357
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Iijima Daisuke¹^ORCID,Sugama Hiroshi¹,Awai Nobumasa¹,Takahashi Yoichi¹,Togashi Yuko¹,Takebe Tohru¹,Xie Jianshu²,Shen Jingkang²,Ke Ying²,Akatsuka Hidenori¹,Kawaguchi Takayuki¹,Takedomi Kei¹^ORCID,Kashima Akiko¹,Nishio Masashi¹,Inui Yosuke¹,Yoneda Hikaru¹,Xia Guangxin²,Iijima Toru¹³^ORCID

Affiliation:

1. Sohyaku, Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 1000 Kamoshida-cho, Aoba-ku, Yokohama 227-0033, Japan

2. Central Research Institute, Shanghai Pharmaceuticals Holding Co., Ltd., Building 5, No. 898 Halei Road, Zhangjiang Hi-tech Park, Pudong New Area, Shanghai 201203, PR China

3. Lead Exploration Unit, Drug Discovery Initiative, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.2c00280

Reference23 articles.

1. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

2. Renin inhibition with aliskiren: where are we now, and where are we going?

3. Direct Renin Inhibitors as a New Therapy for Hypertension

4. Recent advances in the discovery of non-peptidic direct renin inhibitors as antihypertensives: new patent applications in years 2000 – 2008

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of SPH3127: A Novel, Highly Potent, and Orally Active Direct Renin Inhibitor;Journal of Medicinal Chemistry;2022-08-08